Quick Order Cart

Cat. No. ARG0804

HNRNPA2B1 Knockout THP-1 Cell Line

  • Product Type:

    Genome-edited Cells

  • Tissue Source:

    Blood (peripheral blood)

  • Disease:

    Acute monoblastic leukemia

  • Gene Species:

    Homo sapiens (Human)

The HNRNPA2B1 Knockout THP-1 Cell Line is a CRISPR/Cas9-edited knockout model in the human THP-1 monocytic leukemia cell line, designed to study HNRNPA2B1, an RNA-binding protein that connects DNA damage to innate immunity by activating the cGAS-STING pathway. This line allows dissection of HNRNPA2B1-dependent alternative splicing, mRNA trafficking, and its role in type I interferon and NF-kB signaling. It is ideally suited for research in acute myeloid leukemia, innate immune signaling, and spliceosome biology, leveraging THP-1's capacity for macrophage differentiation. Common readouts include RNA-seq, ??-H2AX foci assays, co-immunoprecipitation, cytokine ELISA, and NF-kB reporter assays, enabling comprehensive functional analyses.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    THP-1

    Age

    1 year

    Sex of Donor

    Male

    Gene Name

    HNRNPA2B1

    Gene Species

    Homo sapiens (Human)

    Gene Identifier

    NCBI Gene ID 3181

  • Culture Conditions

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    Daily monitoring confirms that the cells are free from bacterial, yeast, and fungal contamination.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

    Pathogens

    Cells tested negative for HIV-1, HBV, and HCV.

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The HNRNPA2B1 Knockout THP-1 Cell Line is a CRISPR/Cas9-edited loss-of-function model in which the HNRNPA2B1 gene has been disrupted in the human THP-1 monocytic cell line. This stable knockout provides a robust platform for investigating HNRNPA2B1 functions in RNA metabolism, innate immunity, and DNA damage responses without the variability of transient knockdown approaches.

THP-1 is a well-characterized monocytic cell line derived from the peripheral blood of a 1-year-old male with acute monocytic leukemia (FAB M5). It retains the capacity to differentiate into macrophage-like cells upon stimulation, recapitulating key phagocytic and inflammatory properties and serving as a widely used model for monocyte/macrophage biology and leukemogenesis.

HNRNPA2B1 is a nucleocytoplasmic shuttling RNA-binding protein that regulates alternative splicing and mRNA trafficking. It interacts with spliceosome factors U2AF1 and SRSF1 and controls transcript stability. Upon genotoxic stress, HNRNPA2B1 relocalizes to the cytoplasm, binds cytosolic DNA, and activates the cGAS-STING pathway, recruiting TBK1 and IRF3 to drive NF-kB and type I interferon responses. HNRNPA2B1 also forms complexes with DNA-PKcs, KU70, and KU80, and its activity is modulated by DNA damage, interferon-??, and Toll-like receptor ligands, linking DNA repair to innate immune signaling.

In the THP-1 context, ablation of HNRNPA2B1 allows dissection of its roles in leukemic cell proliferation, differentiation, and drug resistance, while simultaneously providing a clean background to study how this DNA sensor impinges on monocyte/macrophage immune effector functions, including phagocytosis and cytokine release governed by NF-kB and cGAS-STING axes.

This knockout cell line is suitable for RNA-seq and alternative splicing analyses to map HNRNPA2B1-dependent transcriptome changes. DNA damage responses can be probed by ??-H2AX foci formation, and co-immunoprecipitation/western blotting enable characterization of interactions with spliceosomal and DNA repair complexes. Functional readouts include NF-kB luciferase reporters, ELISA-based cytokine quantification, and flow cytometric assays for phagocytosis, apoptosis, and cell cycle. Pharmacological screens may identify modulators of HNRNPA2B1-associated pathways. For additional information, contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)